Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342692 | 1.00 | AAK1 (0.33) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL357909 | 1.00 | AAK1 (0.33) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL18419552 | 0.89 | — | — | |
| Biphenyl SCHEMBL27530882 | 0.87 | CYP1A2 (0.41) | MMP13GAAL3MBTL1 | |
| SCHEMBL13006285 | 0.86 | MEN1 (0.31) | MEN1GAAKMT2AHDAC6HDAC1 | |
| SCHEMBL2264821 | 0.86 | MEN1 (0.31) | MEN1GAAKMT2AHDAC6HDAC1 | |
| SCHEMBL2264825 | 0.86 | MEN1 (0.31) | MEN1GAAKMT2AHDAC6HDAC1 | |
| SCHEMBL7876573 | 0.84 | AAK1 (0.32) | AAK1MMP13HDAC6HDAC1HDAC2 | |
| SCHEMBL17277663 | 0.84 | AAK1 (0.32) | AAK1MMP13HDAC6HDAC1HDAC2 | |
| SCHEMBL14952039 | 0.83 | AAK1 (0.33) | AAK1MMP13HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1462 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118085005-A | 18 Beta-glycyrrhetinic acid derivative and preparation method and application thereof | 石河子大学 | 2024-05-28 | — | — | CN | claimed |
| US-20240083846-A1 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-03-14 | — | — | US | claimed |
| CN-109153645-B | Process for preparing 6-alkynyl-pyridine derivatives | 勃林格殷格翰国际有限公司 | 2022-06-21 | — | — | CN | claimed |
| US-11053237-B2 | Process for the manufacture of 6-alkynyl-pyridine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-07-06 | — | — | US | claimed |
| EP-3458441-B1 | PROCESS FOR THE MANUFACTURE OF 6-ALKYNYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2021-01-20 | — | — | EP | claimed |
| US-20190308967-A1 | PROCESS FOR THE MANUFACTURE OF 6-ALKYNYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-10 | — | — | US | claimed |
| EP-3458441-A1 | PROCESS FOR THE MANUFACTURE OF 6-ALKYNYL-PYRIDINE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2019-03-27 | — | — | EP | claimed |
| WO-2017198734-A1 | PROCESS FOR THE MANUFACTURE OF 6-ALKYNYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-23 | — | — | WO | claimed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | claimed |
| CN-105566447-A | Peptoid antagonist of anti-apoptosis protein and synthesis method and application of peptoid antagonist | UNIV GUANGDONG TECHNOLOGY | 2016-05-11 | — | — | CN | claimed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | claimed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-122029166-A | Condensed cyclic compound and harmful arthropod control composition containing the same | 住友化学株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-4260608-A | ANTIMICROBIAL, ANTIMITOTIC, AND ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-04-07 | — | — | US | disclosed |
| EP-0021173-A1 | Maytansinoids, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-01-07 | — | — | EP | disclosed |
| EP-0014402-A1 | Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-08-20 | — | — | EP | disclosed |
| EP-0011276-A1 | Maytansinoids, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1980-05-28 | — | — | EP | disclosed |
| EP-0004466-A1 | Demethyl maytansinoids and methods for producing them | Takeda Chemical Industries, Ltd. (JP) | 1979-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | AAK1 3292/4885MMP13 1620/4885MEN1 3253/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | AAK1 4125/4885MMP13 800/4885MEN1 3255/4885 |
| US-20240083846-A1 | SMAC MIMETICS FOR TREATMENT OF CANCER, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF | BIRC5, BIRC2, BIRC3 | AAK1 2127/4885MMP13 3254/4885MEN1 1280/4885 |
| US-11053237-B2 | Process for the manufacture of 6-alkynyl-pyridine derivatives | ALK, PARP16, ALKBH3 | AAK1 408/4885MMP13 4657/4885MEN1 2522/4885 |
| US-20260109686-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | PARP2, PARP1, PARP11 | AAK1 2899/4885MMP13 3833/4885MEN1 3994/4885 |
| US-20190308967-A1 | PROCESS FOR THE MANUFACTURE OF 6-ALKYNYL-PYRIDINE DERIVATIVES | ALK, PARP16, ALKBH3 | AAK1 408/4885MMP13 4657/4885MEN1 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.